Anthony Magliocco MD’s Post

Oncology Precision Medicine about advancing oncology through precision medicine, I believe in the transformative power of tailored treatments that align with individual patient profiles. By integrating genomic data and innovative #therapies, we can enhance #treatment efficacy and improve patient outcomes. I’m dedicated to collaborating with multidisciplinary teams to drive research and implementation of precision oncology solutions that empower patients in their fight against #cancer. Let's connect to explore the future of cancer care together Get more on : https://lnkd.in/dh3CHS4Z #PrecisionMedicine #Oncology #CancerResearch #PersonalizedMedicine #Genomics #TargetedTherapy #CancerCare #ClinicalTrials #Biomarkers #PatientCentric #HealthcareInnovation #CancerTreatment #Pharmacogenomics #CancerAwareness #FutureOfMedicine

Velsera and Genoks Genetik Hastalıklar Değerlendirme Merkezi are revolutionizing cancer diagnostics and treatment in Turkey and beyond!    By integrating Genoks' expertise in genomics with our Clinical Genomics Workspace (CGW), this collaboration will significantly enhance cancer diagnostic services, empowering clinicians with precise insights for personalized patient care. We are excited to join forces with Genoks to advance oncology diagnostics, impacting cancer treatment and patient outcomes. Read the full press release to learn more about how this partnership is set to transform oncology diagnostics and patient care: https://lnkd.in/eu78dPZc

Oncology trials face a daunting reality: 90% of drugs tested in clinical trials fail to demonstrate efficacy or safety, delaying the development of new treatments. This failure rate is particularly pronounced in cancer research, where the biological complexity of tumors, combined with insufficient trial design, often leads to inconclusive results. TrialKey is designed to tackle these challenges head-on by integrating advanced AI into the clinical trial process. Our platform uses data from over 350,000 cancer trials to refine every aspect of trial design, from optimizing patient stratification based on molecular profiling to predicting trial outcomes with high accuracy. This approach not only enhances the robustness of clinical trials but also helps researchers avoid common pitfalls that lead to failure. In a field where every success could mean saving lives, TrialKey is here to help oncology professionals navigate the complexities of cancer research with greater confidence. Learn more about our approach: https://trialkey.ai/ Book a demo: https://appt.link/minhthu #oncology #cancerresearch #clinicaltrials #drugdiscovery #biotech #cancertherapies #tumorbiology #precisionmedicine #aiinhealthcare #cancertrials #molecularprofiling #cancertreatment #oncologytrials #pharmaresearch

On April 23rd, our sister company Nonacus will be hosting a webinar looking at molecular characterisation in cancer care. Don’t miss this great opportunity to discover how molecular cancer testing is shaping our understanding of cancer evolution, how this aids clinical decision making, and the developments we can expect in the coming years. #FrontLineGenomics #Nonacus #Webinarseries #Oncology

🔬 Advances in Oncological Data Analysis: Transforming Patient Outcomes 🔬 Cancer research and patient care are being revolutionized by the power of data. In our latest blog, we explore how advancements in oncology data analysis are uncovering new therapies and validating existing treatments. From leveraging real-world data to integrating genomic information, these advancements are paving the way for personalized cancer treatment plans. Despite challenges like data integration and privacy concerns, the future of oncology looks promising with data-driven approaches. Learn more about the complexities of oncology data and uncover how it’s shaping the future of cancer care. 🔗 Read the full article: https://bit.ly/46heORs #Oncology #CancerResearch #BigData #PrecisionMedicine #HealthcareInnovation #Bioinformatics #RealWorldData

A HUGE THANK YOU to all oncologists, researchers and biopharma companies who have worked closely with us this year. Thank you for your support and confidence in Guardant Health’s comprehensive genomic profiling tests which are transforming cancer care across all stages of the disease. As we move into 2024, we look forward to your continued support in guiding treatment decisions for patients with cancer in Asia, Middle East and Africa.   Patient centricity is the heart of all that we do. We serve each patient like a family member.   Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.   #guardanthealth #guardanthealthamea #thankyou #oncologists #medicaloncologists #researchers #biopharma #cancerpatients #puttingpatientsfirst #guardant360 #guardant360tissuenext #guardantreveal #guardantresponse #shield #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #liquidissolid

How can we harness “bioinformatics” – tons of cancer patient data and technological advances, especially artificial intelligence -- to discover new treatments, guide treatment decisions, and increase access to all patients? In an ideal world, patients, caregivers, and physicians (and AI working on their behalf) would be able to search a database of the experiences of patients similar to them and help them in their decision-making process about treatment. And researchers would be able to develop more complex biomarkers and processes to predict disease progression and drug response. -- Why/Biological Discovery: We can discover new drug targets, understand why a disease occurs, why it becomes resistant to the drugs we give it, then how we can intervene. -- For Whom/Clinical Guidance: We can personalize treatment plans for cancer patients: who should get what drug, where should that decision-making be done, and how algorithms can guide them. -- How/Equitable Implementation: We can do this so that everyone, near and far, can experience it, and not just a select few patients who happen to lock into a clinical trial or happen to be living near a big quaternary care cancer center. We can bridge the gap between data/AI/computational tools and clinical applications in the long term. Medical oncologist and computational biologist Dr. Eli Van Allen is uniquely qualified to describe the landscape of patient data repositories and translating that data into clinical use. He is an institute member at the Broad Institute of MIT and Harvard, Scientific Champion for Count Me In, an associate professor of medicine at Harvard Medical School, and chief of the Division of Population Sciences at the Dana-Farber Cancer Institute. For more, please see https://lnkd.in/eDJGKdSe

You’re invited! Join us April 30 – May 2 for our virtual event highlighting the role of genomics tools in transforming oncology research. We’ll be hosting various activities, including: 💻Webinars: Improve FFPE and liquid biopsy processing and streamline viral-vector development for cancer therapeutics with our oncology-focused webinars 🗨️Live Discussions: Join industry experts for a live roundtable as they discuss improving Minimal Residual Disease (MRD) detection with cutting-edge NGS tools 🏆Grants: Enter to win one of four grants totaling $25,000 as we recognize excellence in oncology research. Together, we can advance oncology research and make a difference in the lives of those affected by cancer. Join the event: https://hubs.ly/Q02ryQ8f0 #Oncology #CancerResearch #Genomics #NGS #PrecisionMedicine

Transforming Clinical Oncology Research with Advanced Genomics! Why Choose Our OncoPanels? ⚡ Rapid and cost-effective analysis 🔗 Comprehensive biomarker detection in a single workflow 💎 Empowering precision oncology with the Thermo Fisher Ion S5 platform Take your clinical oncology research to new heights! Let's push the boundaries of cancer diagnostic research together. #OncologyResearch #OncoPanels #Oncomine #PrecisionMedicine #CancerDiagnostics #Genomics #Nucleome #ThermoFisher #ClinicalOncology #TargetedTherapies

Through next-day NGS, we are helping accelerate AML and MDS treatment strategies in the National Cancer Institute's groundbreaking myeloMATCH precision medicine umbrella trial. This program leverages rapid #genomictesting to more quickly match patients battling aggressive, life-threatening cancers with the appropriate treatment. Find out how our next-generation sequencing is helping to advance emerging precision medicines through studies in #oncology to make a difference in the lives of patients. #thermofisheremp